This is the authors' abstract. We don't add key points for this paper.
This study evaluated whether hyoscine N-butylbromide administration before colostrum feeding could influence colostral immunoglobulin G (IgG) absorption and passive transfer in neonatal Jersey calves. Eighteen clinically healthy calves were allocated to a control group ( n = 6) or a hyoscine N-butylbromide-treated group ( n = 12). Treated calves received hyoscine N-butylbromide at 0.4 mg/kg intramuscularly 15–30 min before the first colostrum feeding. All calves received high-quality maternal colostrum (Brix ≥25%) within 6 h after birth. Serum Brix was measured at 48 h, and the same serum samples were analyzed for IgG, total protein, gamma-glutamyl transferase (GGT), and glucose. Treated calves had higher serum Brix than controls at 48 h (10.96 ± 0.81 vs. 9.53 ± 0.7%; p = 0.002). Serum IgG was also higher in treated calves at 48 h (3,243 ± 794 vs. 2,175 ± 1,150 mg/dL; p = 0.034), whereas total protein, GGT, and glucose did not differ between groups ( p ≥ 0.217). These preliminary findings suggest that hyoscine N-butylbromide administration before colostrum feeding may be associated with improved passive transfer indicators in neonatal calves; however, confirmation in larger, adequately powered studies is required.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
BAŞER et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: